PMID- 18473355
OWN - NLM
STAT- MEDLINE
DCOM- 20080721
LR  - 20220408
IS  - 0008-543X (Print)
IS  - 0008-543X (Linking)
VI  - 113
IP  - 1
DP  - 2008 Jul 1
TI  - Bronchopulmonary neuroendocrine tumors.
PG  - 5-21
LID - 10.1002/cncr.23542 [doi]
AB  - Bronchopulmonary neuroendocrine tumors (BP-NETs) comprise approximately 20% of 
      all lung cancers and represent a spectrum of tumors arising from neuroendocrine 
      cells of the BP-epithelium. Although they share structural, morphological, 
      immunohistochemical, and ultrastructural features, they are separated into 4 
      subgroups: typical carcinoid tumor (TC), atypical carcinoid tumor (AC), 
      large-cell neuroendocrine carcinoma (LCNEC), and small-cell lung carcinoma 
      (SCLC), which exhibit considerably different biological characteristics. The 
      clinical presentation includes cough, hemoptysis, and obstructive pneumonia but 
      varies depending on site, size, and growth pattern. Less than 5% of BP-NETs 
      exhibit hormonally related symptoms such as carcinoid syndrome, Cushing, 
      acromegaly, and SIADH. SCLC is the most common BP-NET, while LCNEC is rare, 
      approximately 10% and < or =1%, respectively, of all lung cancers. Both SCLC and 
      LCNEC progress rapidly, are aggressively metastatic, and exhibit a poor 
      prognosis. The incidence of BP-carcinoids (TC and AC) in the US was 1.57 of 
      100,000 in 2003 (an unexplained and substantial increase over the last 30 years, 
      approximately 6% per year). No curative treatment except for radical surgery 
      (almost never feasible) exists. The slow-growing TC exhibit a fairly good 
      prognosis ( approximately 88%, 5-year survival), whereas AC demonstrate a 5-year 
      survival of approximately 50%, and the highly malignant LCNEC and SCLC5-year 
      survival of 15% to 57% and <5%, respectively. This review provides a broad 
      overview on BP-NETs and focuses on the evolution of the disease, general 
      features, and current diagnostic and therapeutic options.
CI  - (Copyright) 2008 American Cancer Society.
FAU - Gustafsson, Bjorn I
AU  - Gustafsson BI
AD  - Department of Surgery, Yale University School of Medicine, New Haven, CT 
      06520-8062, USA.
FAU - Kidd, Mark
AU  - Kidd M
FAU - Chan, Anthony
AU  - Chan A
FAU - Malfertheiner, Max V
AU  - Malfertheiner MV
FAU - Modlin, Irvin M
AU  - Modlin IM
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Cancer
JT  - Cancer
JID - 0374236
SB  - IM
MH  - Bronchial Neoplasms/diagnosis/genetics/pathology/therapy
MH  - Carcinoid Tumor/diagnosis/genetics/pathology/therapy
MH  - Carcinoma, Large Cell/diagnosis/genetics/pathology/therapy
MH  - Carcinoma, Small Cell/diagnosis/genetics/pathology/therapy
MH  - Humans
MH  - *Lung Neoplasms/diagnosis/genetics/pathology/therapy
MH  - Models, Biological
MH  - Neoplasm Metastasis
MH  - *Neuroendocrine Tumors/diagnosis/genetics/pathology/therapy
MH  - Prognosis
RF  - 134
EDAT- 2008/05/14 09:00
MHDA- 2008/07/22 09:00
CRDT- 2008/05/14 09:00
PHST- 2008/05/14 09:00 [pubmed]
PHST- 2008/07/22 09:00 [medline]
PHST- 2008/05/14 09:00 [entrez]
AID - 10.1002/cncr.23542 [doi]
PST - ppublish
SO  - Cancer. 2008 Jul 1;113(1):5-21. doi: 10.1002/cncr.23542.